Raj Long presented on regulatory challenges for dementia treatment development and proposed innovative regulatory approaches. Key challenges included the prolonged time required for R&D, uncertainties around classifying and measuring dementia, and regulatory variances between geographies. These factors increase costs and risks for pharmaceutical companies, deterring investment. To address this, Long suggested regulatory designations to expedite review, adaptive development and licensing models, increased international regulator collaboration, incentives for developers, and public-private partnerships to accelerate cure discovery by 2025. Current approaches were deemed insufficient given the high risks and costs of dementia R&D.